366 related articles for article (PubMed ID: 18230058)
21. Everolimus and pazopanib: two new drugs for renal cell cancer.
Med Lett Drugs Ther; 2010 May; 52(1337):33-4. PubMed ID: 20431519
[No Abstract] [Full Text] [Related]
22. Drug insight: advances in renal cell carcinoma and the role of targeted therapies.
Larkin JM; Chowdhury S; Gore ME
Nat Clin Pract Oncol; 2007 Aug; 4(8):470-9. PubMed ID: 17657252
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib in renal cell carcinoma.
Flaherty KT
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):747s-752s. PubMed ID: 17255304
[TBL] [Abstract][Full Text] [Related]
24. Temsirolimus in renal cell carcinoma.
Otto T; Eimer C; Gerullis H
Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
[TBL] [Abstract][Full Text] [Related]
25. Pazopanib: a review of its use in the management of advanced renal cell carcinoma.
McCormack PL
Drugs; 2014 Jul; 74(10):1111-25. PubMed ID: 24935162
[TBL] [Abstract][Full Text] [Related]
26. Pazopanib: a novel multitargeted tyrosine kinase inhibitor.
Sonpavde G; Hutson TE
Curr Oncol Rep; 2007 Mar; 9(2):115-9. PubMed ID: 17288876
[TBL] [Abstract][Full Text] [Related]
27. Nursing considerations for patients receiving pazopanib for renal cell carcinoma.
Becze E
ONS Connect; 2012 Feb; 27(2):16-7. PubMed ID: 22375508
[No Abstract] [Full Text] [Related]
28. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma.
Rini BI; Flaherty K
Urol Oncol; 2008; 26(5):543-9. PubMed ID: 18774471
[TBL] [Abstract][Full Text] [Related]
29. Kinase inhibitors in the treatment of renal cell carcinoma.
Larkin JM; Eisen T
Crit Rev Oncol Hematol; 2006 Dec; 60(3):216-26. PubMed ID: 16860997
[TBL] [Abstract][Full Text] [Related]
30. Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
Shantakumar S; Nordstrom BL; Djousse L; Hall SA; Gagnon DR; Fraeman KH; van Herk-Sukel M; Chagin K; Nelson J
Cancer Chemother Pharmacol; 2016 Sep; 78(3):559-66. PubMed ID: 27438066
[TBL] [Abstract][Full Text] [Related]
31. [Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas].
Gennigens C; Jerusalem G
Rev Med Liege; 2012; 67(7-8):437-42. PubMed ID: 22984765
[TBL] [Abstract][Full Text] [Related]
32. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
Kapoor A; Figlin RA
Cancer; 2009 Aug; 115(16):3618-30. PubMed ID: 19479976
[TBL] [Abstract][Full Text] [Related]
33. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.
Xu CF; Bing NX; Ball HA; Rajagopalan D; Sternberg CN; Hutson TE; de Souza P; Xue ZG; McCann L; King KS; Ragone LJ; Whittaker JC; Spraggs CF; Cardon LR; Mooser VE; Pandite LN
J Clin Oncol; 2011 Jun; 29(18):2557-64. PubMed ID: 21576632
[TBL] [Abstract][Full Text] [Related]
34. Pazopanib: in advanced renal cell carcinoma.
Sanford M; Keating GM
BioDrugs; 2010 Oct; 24(5):279-86. PubMed ID: 20649181
[TBL] [Abstract][Full Text] [Related]
35. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
Brotelle T; Bay JO
Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.
Hutson TE; Davis ID; Machiels JP; De Souza PL; Rottey S; Hong BF; Epstein RJ; Baker KL; McCann L; Crofts T; Pandite L; Figlin RA
J Clin Oncol; 2010 Jan; 28(3):475-80. PubMed ID: 20008644
[TBL] [Abstract][Full Text] [Related]
37. Treatment of metastatic renal cell carcinoma.
Reeves DJ; Liu CY
Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
[TBL] [Abstract][Full Text] [Related]
38. Combination targeted therapy in advanced renal cell carcinoma.
Sosman J; Puzanov I
Cancer; 2009 May; 115(10 Suppl):2368-75. PubMed ID: 19402058
[TBL] [Abstract][Full Text] [Related]
39. Pazopanib for the treatment of breast cancer.
Amiri-Kordestani L; Tan AR; Swain SM
Expert Opin Investig Drugs; 2012 Feb; 21(2):217-25. PubMed ID: 22233389
[TBL] [Abstract][Full Text] [Related]
40. Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma.
Asaithambi G; Peters BR; Hurliman E; Moran BP; Khan AS; Taylor RA
J Clin Pharm Ther; 2013 Apr; 38(2):175-6. PubMed ID: 23210935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]